Welcome to our dedicated page for Syndax Pharmaceuticals SEC filings (Ticker: SNDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Syndax Pharmaceuticals filings document regulatory disclosures for a commercial-stage cancer-therapy company. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary financial information, product-revenue updates for Revuforj and Niktimvo, business presentations and material product events, including the FDA approval of Revuforj for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation.
The company’s proxy materials cover board elections, executive compensation, equity-award valuation and shareholder voting matters. Other material-event filings address governance changes, including director departures, and Regulation FD disclosures tied to investor presentations and operating updates.
Syndax Pharmaceuticals (Nasdaq:SNDX) filed an 8-K under Item 5.02 reporting the resignation of director William Meury, effective June 24 2025. Meury stepped down to become President, CEO and board member of Incyte Corporation, Syndax’s collaboration partner on Niktimvo™ (axatilimab-csfr). The company states the departure involves no disagreements regarding its operations, policies or practices. No successor or board-composition changes were disclosed.
While day-to-day operations and partnership terms remain unchanged, investors should watch for follow-up filings detailing any replacement director or shifts in oversight of the Incyte collaboration.